Comparative Pharmacology
Head-to-head clinical analysis: NESACAINE MPF versus SYNERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESACAINE MPF versus SYNERA.
NESACAINE-MPF vs SYNERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Tetracaine is an ester-type local anesthetic that similarly inhibits sodium channels. The combination provides local dermal anesthesia.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
Apply 1 patch (70 mg lidocaine and 70 mg tetracaine) to intact skin over the intended venipuncture site or superficial dermatologic procedure site 20-30 minutes prior to procedure; maximum 1 patch per procedure.
None Documented
None Documented
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Lidocaine: 1.5–2 hours; prilocaine: 1–1.5 hours. Terminal half-life similar for both. Note: prolonged in hepatic impairment or neonates.
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Renal excretion of lidocaine and prilocaine metabolites: lidocaine <10% unchanged, prilocaine negligible unchanged. Metabolites primarily renal.
Category C
Category C
Local Anesthetic
Local Anesthetic